Complications of myeloma and its treatments

Chemotherapy treatment of multiple myeloma patients increases circulating levels of endothelial microvesicles. Hall J et al. Thromb Res. 2016 Aug 17;146:20-22. doi: 10.1016/j.thromres.2016.08.017. [Epub ahead of print]. Diarrhea in Multiple Myeloma: A Review of the Literature. Faiman B et al. Clin J Oncol Nurs. 2016 Aug 1;20(4):E100-5. doi: 10.1188/16.CJON.E100-E105. Secondary malignancies in patients with multiple myeloma, Waldenström macroglobulinemia and monoclonal gammopathy of undetermined significance. Castillo…

Journal, Library, Management of complications & side effects

Current treatments

The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents. Chakraborty R et al. Bone Marrow Transplant. 2016 Aug 22. doi: 10.1038/bmt.2016.214. [Epub ahead of print]. Plerixafor for autologous stem-cell mobilization and transplantation for patients in Ontario. Kouroukis CT et al. Curr Oncol. 2016 Aug;23(4):e409-30. doi: 10.3747/co.23.3137. Epub 2016 Aug 12. Mobilization of autologous…

Journal, Library

Revamped Cancer Drugs Fund launched in England

A revised Cancer Drugs Fund (CDF) together with wider changes in the way the National Institute for Health and Care Excellence (NICE) assesses cancer drugs has recently been launched. Developed through a partnership between National Health Service (NHS) England and NICE, the new CDF allows drugs which meet set criteria under a managed access agreement…

News

Diagnostic tests and prognostic indicators

Clinicopathological significance of p15 promoter hypermethylation in multiple myeloma: a meta-analysis. Wei B et al. Onco Targets Ther. 2016 Jul 1;9:4015-22. doi: 10.2147/OTT.S102733. eCollection 2016. RGS1 expression is associated with poor prognosis in multiple myeloma. Roh J et al. J Clin Pathol. 2016 Jul 21. pii: jclinpath-2016-203713. doi: 10.1136/jclinpath-2016-203713. [Epub ahead of print]. Diagnostic performances of M-protein tests according to the clinical presentations…

Diagnosing and Monitoring Myeloma, Journal, Library

Related conditions

Rationale, application, and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis. Merlini G et al. Leukemia. 2016 Jul 15. doi: 10.1038/leu.2016.191. [Epub ahead of print]. Bridging the Divide: An Onco-Nephrologic Approach to the Monoclonal Gammopathies of Renal Significance. Hogan JJ et al. Clin J Am Soc Nephrol. 2016 Jul 14. pii:…

Journal, Library

Biology and genetics

Multiple myeloma-derived Jagged ligands increases autocrine and paracrine interleukin-6 expression in bone marrow niche. Colombo M et al. Oncotarget. 2016 Jul 24. doi: 10.18632/oncotarget.10820. [Epub ahead of print]. HLA polymorphism and risk of multiple myeloma. Beksac M et al. Leukemia. 2016 Jul 27. doi: 10.1038/leu.2016.199. [Epub ahead of print]. Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs. Ito T et…

Journal, Library, Management of Myeloma

General

The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders. Citrin R et al. Expert Rev Hematol. 2016 Jul 22. [Epub ahead of print]. A new era of immune therapy in multiple myeloma. Tai YT et al. Blood. 2016 Jul 21;128(3):318-9. doi: 10.1182/blood-2016-06-719856. The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a “real-world” study: the Royal Marsden…

Journal, Library